Takeda’s success with a dengue vaccine comes with caveats
Sanofi’s decades-long efforts to develop a vaccine for dengue resulted in a global scandal. Takeda is looking to succeed where its rival stumbled, but the company’s success story is nuanced.
As STAT’s Ed Silverman reports, preliminary data on Takeda’s vaccine suggest it’s effective, but experts are holding out for longer-term results before drawing any conclusions. For one, safety issues could emerge over time. But then there’s the legacy of Sanofi’s vaccine, which turned out to pose serious risks to patients who hadn’t already been exposed to dengue. That doesn’t appear to be a problem for Takeda, but only time will tell.
“Let’s make sure nobody runs around claiming an early Pyrrhic victory,” said Scott Halstead, a retired dengue expert.
Read more.
As STAT’s Ed Silverman reports, preliminary data on Takeda’s vaccine suggest it’s effective, but experts are holding out for longer-term results before drawing any conclusions. For one, safety issues could emerge over time. But then there’s the legacy of Sanofi’s vaccine, which turned out to pose serious risks to patients who hadn’t already been exposed to dengue. That doesn’t appear to be a problem for Takeda, but only time will tell.
“Let’s make sure nobody runs around claiming an early Pyrrhic victory,” said Scott Halstead, a retired dengue expert.
Read more.
No hay comentarios:
Publicar un comentario